In addition, peptide polyagonists (i.e., synthetic molecules that combine the amino acid sequences of more than one peptide, thus having the ability to bind to more than one receptor), such as tirzepatide (LY3298176) [a dual GLP-1RA and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist] have also been introduced into the management of metabolic diseases, including T2DM and obesity, and also are under investigation for NAFLD with high expectations [7]
Crosstalk between diabetes and brain: Glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration
External Research References PubMed Semaglutide Studies PMC Semaglutide Mechanism Review PubChem Semaglutide Compound Page Wikipedia Semaglutide ScienceDirect Semaglutide Articles Semaglutide 1mg 5 Vials Research Product Documentation Semaglutide 1mg 5 Vials is presented here as a research product for laboratory documentation, product-identification review, and analytical context
Wegovy (semaglutide): Patients on the 2.4 mg dose lost an average of 15% of their body weight over 68 weeks
Note: Its important to distinguish between Type 2 Diabetes and Type 1 Diabetes